NGS enables broad detection of known and novel viruses in a single assay. Its high sensitivity, specificity, and scalability can meet GMP throughput levels.
- The Promise Of MRD-Guided CAR-T Treatment
- CDMO Quality Oversight: How FDA And Pharma Leaders Are Rethinking Data, AI, And Culture
- Autoimmune CAR T Has Hit A Critical Moment. Are We Asking The Right Questions?
- A QMS That Anticipates Cell And Gene Therapy Quality Challenges
- Using Digital Platforms To Find Your CDMO
- July 2026 — CDMO Opportunities And Threats Report
- ADC CDMO Selection For Small Biotech
- Implementing AI Solutions In GMP While Managing Risk
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Determining The True Cost Of Single-Use Fluid Management
Looking beyond unit price reveals how reliability, leak prevention, and shelf life affect bioprocessing costs. Make purchasing decisions that support resilient and predictable operations.
-
How Innovative Valve Design Drives Efficiency And Product Protection
Thoughtful design at the bioreactor and ATF interface can reduce shear, simplify fluid paths, and conserve space. See how rethinking an overlooked valve assembly helped improve process efficiency.
-
Decentralized And Community-Based Solutions Driving Women's Healthcare
Clinical trials should reflect the affected population by reducing participation barriers and bringing trials to patients to increase inclusion and improve real-world data.
-
Molecular Approaches To Streamline Cell Therapy Product Analytical Testing
Learn how rapid molecular methods of cell therapy testing like qPCR for mycoplasma, sterility, and lentiviral quantification are key to accelerating product release and timely treatment delivery.
-
Best Practices For Oncolytic Virus Design, Development, Manufacturing
Oncolytic viruses have the potential to revolutionize standard cancer treatment, but their continued progress hinges on meeting a number of goals linked to safety, efficacy, and commercial scale-up.
-
Revolutionizing Lentiviral Vector Manufacturing For In Vivo, Ex Vivo CAR-T Therapies
Discover how scalable, cost-effective, and high-quality lentiviral vector manufacturing can accelerate both ex vivo and emerging in vivo CAR-T therapies.
-
NGS Analysis Of Hereditary Cancer Predispositions
Examine how a molecular genetics team improves NGS efficiency and library quality through streamlined automation, intuitive QC tools, and reliable workflows, boosting reproducibility.
-
New Robot-Compatible Sterile Connectors Enhance Cell Therapy Manufacturing
Discover how automating sterile fluid transfers removes human contamination risks, solves operator shortages, and reduces cell therapy manufacturing costs by up to 74%.
-
Cleanroom Recovery. Proven Results. Contamination Control Case Studies
Through this collection, review how a proven, automated solution can help facilities stay compliant, operational, and protected — whether in a crisis or during planned maintenance.
-
USP <665> Becomes Official On May 1, 2026. Are You Ready?
With USP <665> becoming official on May 1, 2026, proactive preparation is essential to ensure compliance and prevent delays, regulatory observations, or supply chain disruptions.
NEWSLETTER ARCHIVE
- 09.09.26 -- Smarter Ways To Reduce Risk, Downtime, And Lifecycle Surprises
- 09.09.26 -- From CRISPR Breakthroughs To Scalable RNA Therapeutics
- 09.09.26 -- Beyond The Contract: Strategic Steps For eQMS Adoption
- 09.08.26 -- Cell Therapy Advances And Biotech Leadership With Nkarta's Paul Hastings
- 09.08.26 -- Choose New Analytical Technologies At The Right Stage Of Development
- Autoimmune CAR T Has Hit A Critical Moment. Are We Asking The Right Questions?
- Why Celcuity's REVTORPYK Creates A New Path For Precision Oncology
- In Vivo CAR T Needs More Than Better Cell Engineering
- Reimagining Solid Tumor Immunotherapy With SRC-3-Edited Tregs
- Building Antigen-Specific Immune Tolerance For Autoimmune Disease
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections